Actuate Therapeutics (ACTU) Stock: Buy, Sell, or Hold?
ACTU - Actuate Therapeutics, Inc. Common stock
$0.50
-0.06 (-11.44%)
▼
5d:
-0.4%
30d:
-31.94%
90d:
-57.81%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 12, 2026
20d
Get Alerted When ACTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ACTU shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ACTU shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ACTU is currently trading at $0.50, which is considered oversold relative to its 30-day fair value range of $0.59 to $0.97.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $0.41, while resistance sits at $0.72. Short-term momentum is weak, with the stock down 11.4% recently.
Market Sentiment: ACTU scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.68 (+1978.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $0.41, while resistance sits at $0.72. Short-term momentum is weak, with the stock down 11.4% recently.
Market Sentiment: ACTU scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.68 (+1978.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.59 -
$0.97
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-11.4%)
- BULLISH: Trading 1978.1% below Wall St target ($11.68)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.59 -
$0.97
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.41
Resistance Level
$0.72
Current Trend
Strong Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.85
Wall Street Target
$11.68
(+1978.1%)
Share & Embed Analysis
Last updated: October 22, 2026 1:21 PM ET
Data refreshes hourly during market hours. Next update: 2:21 PM
Data refreshes hourly during market hours. Next update: 2:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 61 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
23 analysts |
$86 | 66 BUY |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
